Tupin Emmanuel
Account Manager/Scientific Advisor; Vironova AB; Stockholm, Sweden.
Hum Vaccin Immunother. 2013 Sep;9(9):2009-12. doi: 10.4161/hv.25934. Epub 2013 Jul 29.
On the 15-17th of May 2013, about 120 scientists, postdoctoral fellows and professors representing renowned academic institutes and senior scientists and executives from small biotechs, contract research organizations (CROs) and Big Pharma companies, gathered at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland for the 4th international conference on Modern Vaccines and Adjuvants Formulation. Despite this relative small number, the speakers and attendees covered together a very broad field of expertise. Indeed, experts in microbiology, immunology, biochemistry, formulation, virus and nanoparticle characterization, vaccine production, quality control as well as regulatory professionals attended the conference and were able to present their works and discuss new developments within the field of vaccine and adjuvant development, characterization and approval process. This broad diversity was a highpoint of the conference and allowed for a stimulating environment and underlined the complexity of the challenges that the field currently faces in order to develop better or completely new vaccines and adjuvants.
2013年5月15日至17日，约120名科学家、博士后研究员和教授齐聚瑞士洛桑的沃州大学中心医院（CHUV），他们分别来自知名学术机构，还有小型生物技术公司、合同研究组织（CRO）和大型制药公司的资深科学家与管理人员，共同参加了第四届现代疫苗与佐剂制剂国际会议。尽管人数相对较少，但发言者和与会者涵盖了非常广泛的专业领域。实际上，微生物学、免疫学、生物化学、制剂学、病毒与纳米颗粒表征、疫苗生产、质量控制等领域的专家以及监管专业人士都参加了此次会议，并能够展示他们的工作成果，讨论疫苗与佐剂研发、表征及审批过程领域的新进展。这种广泛的多样性是会议的一大亮点，营造了一个激励人心的环境，也凸显了该领域目前在开发更好或全新疫苗及佐剂方面所面临挑战的复杂性。
